Market Closed - Japan Exchange 07:30:00 03/07/2026 BST 5-day change 1st Jan Change
1,558.50 JPY -0.48% Intraday chart for Nipro Corporation -3.94% +5.52%

Valuation: Nipro Corporation

Market Cap 254B 1.58B 1.38B 1.27B 1.18B 2.24B 150B 2.27B 15.2B 5.91B 73.76B 5.92B 5.79B P/E 2026
18.7x
P/E 2027 * 19.2x
Enterprise Value 750B 4.65B 4.06B 3.73B 3.48B 6.6B 443B 6.7B 44.83B 17.43B 218B 17.45B 17.07B EV / Sales 2026
1.21x
EV / Sales 2027 * 1.1x
Free-Float
87.38%
Yield 2026
1.87%
Yield 2027 * 2.13%
05-12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
05-12 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
05-01 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
03-11 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
02-09 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12-24 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
11-10 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
10/06/25 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
09/06/25 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
13/05/25 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
12/05/25 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2025 and Fiscal Year Ending March 31, 2026 CI
12/05/25 Nipro Corporation Announces Dividend for the Year Ended March 31, 2025, Effective June 27, 2025; Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026 CI
12/05/25 Nipro Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026 CI
1 day-0.48%
1 week-3.94%
Current month-1.14%
1 month-8.97%
3 months-3.53%
6 months+5.52%
Current year+5.52%
1 week 1,531
Extreme 1531
1,635
1 month 1,531
Extreme 1531
1,754.5
Current year 1,401
Extreme 1401
1,760.5
1 year 1,304
Extreme 1304
1,760.5
3 years 1,001.5
Extreme 1001.5
1,760.5
5 years 987
Extreme 987
1,760.5
10 years 908
Extreme 908
1,760.5
Manager TitleAgeSince
President 58 25/06/2025
Chief Administrative Officer 57 25/06/2025
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 81 25/06/2025
Director/Board Member 53 31/05/2009
Director/Board Member 58 31/05/2009
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%-3.94%+19.75%+52.87% 1.59B
+3.49%+2.32%-28.86%-12.49% 166B
-1.43%+3.32%-5.77%-5.57% 106B
+2.80%+3.33%+1.83%+54.09% 57.69B
+1.33%-0.73%+56.39%+51.86% 53.2B
+0.30%+4.43%-10.83%-40.12% 43.56B
+3.50%+14.35% - - 36.52B
-1.21%+3.79%-14.75%-44.56% 27.49B
+0.55%+5.53%+65.33%-4.37% 25.84B
-9.53%+3.61%-8.42%-3.01% 21.27B
Average +2.55%+3.38%+8.30%+5.41% 53.98B
Weighted average by Cap. +3.30%+3.27%-3.26%+0.29%

Financials

2026 2027 *
Net sales 662B 4.1B 3.59B 3.3B 3.07B 5.83B 391B 5.91B 39.56B 15.38B 192B 15.4B 15.07B 696B 4.31B 3.77B 3.47B 3.23B 6.13B 411B 6.22B 41.61B 16.18B 202B 16.2B 15.85B
Net income 14.65B 90.83M 79.4M 72.97M 68.02M 129M 8.65B 131M 876M 341M 4.25B 341M 334M 13.75B 85.25M 74.53M 68.49M 63.84M 121M 8.12B 123M 822M 320M 3.99B 320M 313M
Net Debt 495B 3.07B 2.69B 2.47B 2.3B 4.36B 292B 4.43B 29.63B 11.52B 144B 11.53B 11.28B 510B 3.16B 2.77B 2.54B 2.37B 4.49B 301B 4.56B 30.51B 11.86B 148B 11.88B 11.62B
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
39,168
Date Price Change Volume
03/07/26 JP¥1,558.50 -0.48% 456,000
02/07/26 JP¥1,566.00 +2.09% 693,900
01/07/26 JP¥1,534.00 -2.70% 704,000
30/06/26 JP¥1,576.50 -2.23% 666,800
29/06/26 JP¥1,612.50 +0.44% 543,100
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,558.50JPY
Average target price
1,876.00JPY
Spread / Average Target
+20.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 8086 Stock